Sangamo Therapeutics annual debt-to-equity ratio
2018
2019
2020
2021
2022
2023
2024
Sangamo Therapeutics Debt-to-Equity Ratio Growth & History (SGMOQ)
Sangamo Therapeutics's debt-to-equity ratio was 1.34 for fiscal 2024.
View full Sangamo Therapeutics company overviewSangamo Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 1.34 | 0.88 | +192.01% |
| 2023 | 2023-12-31 | 0.46 | 0.31 | +214.55% |
| 2022 | 2022-12-31 | 0.15 | 0.02 | +14.09% |
| 2021 | 2021-12-31 | 0.13 | 0.04 | +51.65% |
| 2020 | 2020-12-31 | 0.08 | −0.02 | −17.72% |
| 2019 | 2019-12-31 | 0.10 | 0.03 | +35.89% |
| 2018 | 2018-12-31 | 0.08 | — | — |
Sangamo Therapeutics quarterly debt-to-equity ratio
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 4.07 | 3.36 | +474.78% |
| Q2 2025 | 2025-06-30 | 1.20 | −0.03 | −2.55% |
| Q1 2025 | 2025-03-31 | 5.07 | 4.53 | +832.87% |
| Q4 2024 | 2024-12-31 | 1.34 | 0.88 | +192.01% |
| Q3 2024 | 2024-09-30 | 0.71 | 0.45 | +173.32% |
| Q2 2024 | 2024-06-30 | 1.23 | 1.07 | +688.96% |
| Q1 2024 | 2024-03-31 | 0.54 | 0.43 | +383.85% |
| Q4 2023 | 2023-12-31 | 0.46 | 0.31 | +214.55% |
| Q3 2023 | 2023-09-30 | 0.26 | 0.13 | +101.84% |
| Q2 2023 | 2023-06-30 | 0.16 | 0.03 | +19.31% |
| Q1 2023 | 2023-03-31 | 0.11 | −0.02 | −12.23% |
| Q4 2022 | 2022-12-31 | 0.15 | 0.02 | +14.09% |
| Q3 2022 | 2022-09-30 | 0.13 | 0.03 | +30.01% |
| Q2 2022 | 2022-06-30 | 0.13 | 0.04 | +40.76% |
| Q1 2022 | 2022-03-31 | 0.13 | 0.04 | +42.17% |
| Q4 2021 | 2021-12-31 | 0.13 | 0.04 | +51.65% |
| Q3 2021 | 2021-09-30 | 0.10 | 0.02 | +23.52% |
| Q2 2021 | 2021-06-30 | 0.09 | 0.01 | +11.27% |
| Q1 2021 | 2021-03-31 | 0.09 | −0.02 | −18.39% |
| Q4 2020 | 2020-12-31 | 0.08 | −0.02 | −17.72% |
| Q3 2020 | 2020-09-30 | 0.08 | −0.02 | −23.13% |
| Q2 2020 | 2020-06-30 | 0.08 | −0.02 | −15.78% |
| Q1 2020 | 2020-03-31 | 0.11 | 0.07 | +147.89% |
| Q4 2019 | 2019-12-31 | 0.10 | 0.03 | +35.89% |
| Q3 2019 | 2019-09-30 | 0.10 | — | — |
| Q2 2019 | 2019-06-30 | 0.10 | — | — |
| Q1 2019 | 2019-03-31 | 0.04 | — | — |
| Q4 2018 | 2018-12-31 | 0.08 | — | — |
Sangamo Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Sangamo Therapeutics's debt-to-equity ratio increased from 0.10 to 1.34, a change of 1.24. The latest reported quarter, Q3 2025, shows 4.07.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sangamo Therapeutics source filings ↗